Jasper Therapeutics, Inc. — Director's Dealing 2021

Oct 1, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Jasper Therapeutics, Inc. (JSPR)
CIK: 0001788028
Period of Report: 2021-09-24

Reporting Person: Heller Kevin N. (EVP, Research and Development)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.71	2030-09-01	Common Stock (657769)		Direct

Footnotes

F1: 25% of the original number of shares subject to the option vested on August 10, 2021, and 1/48th of the original number of shares have vested and shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.